Skip to content

roztwór do wstrzykiwań

DRUG9 trials

Sponsors

Janssen - Cilag International, Novartis Pharma AG, Wroclaw Medical University, Instytut Matki I Dziecka, Medical University Of Bialystok

Conditions

Advanced throat and larynx cancerDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCLDiffuse large B-cell lymphomas (DLBCLEGFR-mutated Advanced or Metastatic Non-small Cell Lung CancerHigh-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationRare and ultra-rare glomerulonephritisRelapsing multiple sclerosis (RMS)Sarcopenia is characterized by loss of the muscle mass and function. It develops with age and is associated with a high risk of functional loss in complex activities of daily living

Phase 2

Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated with Amivantamab, an EGFR-MET bispecific antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
Active, not recruitingCTIS2023-506578-11-00
Janssen - Cilag InternationalEGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer
Start: 2023-04-25Target: 60Updated: 2025-11-07
Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of nandrolone decanoate therapy and therapy with complex physiotherapy and diet in the treatment of sarcopenia
RecruitingCTIS2024-517178-48-00
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicherand mortality in older adults., deterioration and quality of life, falls and injuries +3
Start: 2023-03-15Target: 168Updated: 2024-10-31
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
Not yet recruitingCTIS2024-518275-64-00
Instytut Hematologii I TransfuzjologiiDiffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL, Diffuse large B-cell lymphomas (DLBCL, High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiation
Target: 340Updated: 2025-11-24
The asssessment of the efficacy of induction radiochemotherapy using low doses of ionizing radiation (iCHRTL) in the treatment of patients with advanced throat and larynx cancer
RecruitingCTIS2024-517480-23-00
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyAdvanced throat and larynx cancer
Start: 2022-02-17Target: 40Updated: 2025-01-31

Phase 3

Phase 4